Edwards Lifesciences/$EW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Ticker
$EW
Sector
Primary listing
NYSE
Employees
15,800
Headquarters
Website
EW Metrics
BasicAdvanced
$46B
11.05
$7.02
1.07
-
Price and volume
Market cap
$46B
Beta
1.07
52-week high
$83.00
52-week low
$64.01
Average daily volume
3.8M
Financial strength
Current ratio
4.682
Quick ratio
3.534
Long term debt to equity
6.38
Total debt to equity
6.863
Interest coverage (TTM)
80.25%
Profitability
EBITDA (TTM)
1,739.3
Gross margin (TTM)
78.87%
Net profit margin (TTM)
72.96%
Operating margin (TTM)
27.95%
Effective tax rate (TTM)
13.55%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
8.42%
Return on equity (TTM)
15.53%
Valuation
Price to earnings (TTM)
11.055
Price to revenue (TTM)
8.054
Price to book
4.32
Price to tangible book (TTM)
6
Price to free cash flow (TTM)
79.228
Free cash flow yield (TTM)
1.26%
Free cash flow per share (TTM)
0.979
Growth
Revenue change (TTM)
9.14%
Earnings per share change (TTM)
188.09%
3-year revenue growth (CAGR)
2.01%
10-year revenue growth (CAGR)
8.86%
3-year earnings per share growth (CAGR)
44.83%
10-year earnings per share growth (CAGR)
26.50%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Bulls say / Bears say
Second-quarter sales grew 11.9% to $1.53 billion (10.6% adjusted), driven by strength across all product groups and exceeding Street expectations (Business Wire)
Transcatheter Mitral and Tricuspid Therapies sales surged 61.9% to $134.5 million, fueled by strong PASCAL and EVOQUE demand and CE Mark approval of the new SAPIEN M3 system (Business Wire)
Edwards raised its full-year sales growth guidance to 9–10% and increased adjusted EPS guidance to the high end of $2.40–$2.50, reflecting confidence in global adoption and upcoming clinical catalysts (Business Wire)
FTC’s lawsuit to block Edwards’ $1.2 billion acquisition of JenaValve could delay entry into the aortic regurgitation device market and incur substantial legal costs, undermining strategic expansion efforts (Reuters)
Edwards recorded a $47.1 million impairment loss in Q2 2025 related to abandoning an option to acquire a cost-method investment, highlighting risks of misallocated capital and potential future write-downs (Business Wire)
Selling, general and administrative expenses jumped 12% year-over-year to $502 million in Q2 2025 and are expected to rise further in H2, which may compress operating margins and reduce free cash flow (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
EW News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Edwards Lifesciences stock?
Edwards Lifesciences (EW) has a market cap of $46B as of September 15, 2025.
What is the P/E ratio for Edwards Lifesciences stock?
The price to earnings (P/E) ratio for Edwards Lifesciences (EW) stock is 11.05 as of September 15, 2025.
Does Edwards Lifesciences stock pay dividends?
No, Edwards Lifesciences (EW) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Edwards Lifesciences dividend payment date?
Edwards Lifesciences (EW) stock does not pay dividends to its shareholders.
What is the beta indicator for Edwards Lifesciences?
Edwards Lifesciences (EW) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.